Neoantigen evolution and response to checkpoint inhibitor immunotherapy in colorectal cancer.

Abstract excerpt

Checkpoint-blockade immunotherapy enables the immune system to recognize tumor cells that were previously invisible due to immune escape, but these therapies lead to heterogeneous patient outcomes. Focusing on colorectal cancer, in which two subtypes have markedly different responses to immunotherapy, we query the relationship between a tumor's mutagenic landscape and therapeutic outcomes. First, we model...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antigens, Neoplasm
• Share to Colorectal Neoplasms
• Share to Immune Checkpoint Inhibitors